Form 4: LAVA Therapeutics Director Sells Shares, Options

LAVA Therapeutics NV Director Kapil Dhingra disposed of 30,000 common shares and 33,390 share options as part of a Purchase Agreement.

Summary

• Director Kapil Dhingra disposed of 30,000 common shares of LAVA Therapeutics NV.
• The disposal was made pursuant to a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• Consideration for the common shares was $1.04 in cash per share plus one non-transferable contingent value right (CVR) per share.
• Kapil Dhingra also cancelled 33,390 in-the-money share options with an exercise price of $0.93.
• The options were cancelled in exchange for a cash amount equal to the excess of $1.04 over the per share exercise price, multiplied by the total number of shares underlying the option, plus one CVR per underlying share.
• Following these transactions, Kapil Dhingra beneficially owns 0 common shares and 0 derivative securities.

Sentiment

Score: 4

Explanation: The filing reports a complete divestment of direct beneficial ownership by a director, which can be viewed with caution by investors, although it is part of a pre-existing agreement involving the issuer.

Negatives

• A director, Kapil Dhingra, has fully divested their direct beneficial ownership in common shares and derivative securities, which could be perceived negatively by the market, despite being part of a pre-arranged company agreement.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The disposal of shares and cancellation of options by Director Kapil Dhingra was executed pursuant to a Purchase Agreement between LAVA Therapeutics NV and XOMA Royalty Corporation. While not a direct related party transaction involving Dhingra, it is a transaction by an insider tied to a company-level agreement.

Stakeholder Impact

• Shareholders: May view a director's complete divestment of direct holdings as a signal, potentially leading to negative sentiment, despite the transaction being part of a broader company agreement.

Key Dates

Keywords

LAVA Therapeutics NV, LVTX, Kapil Dhingra, Insider Trading, Form 4, Share Disposal, Option Cancellation, Contingent Value Right, XOMA Royalty Corporation, Director Transaction